Data from the CheckMate-743 trial has found durable overall survival (OS) rates among pati...

Nivolumab Plus Ipilimumab Demonstrates Durable Overall Survival in Malignant Pleural Mesothelioma – Pharmacy Times

Data from the CheckMate-743 trial has found durable overall survival (OS) rates among patients with first-line unresectable malignant pleural mesothelioma who received nivolumab (Opdivo; Bristol Myers Squibb) and ipilimumab (Yervoy; Bristol Myers Squibb).According to a press release, CheckMate-743 remains the only phase 3 trial to demonstrate a survival improvement with first-line immunotherapy in this patient population, which has now been sustained more 3 years. Data will be featured during the 2021 European Society for Medical Oncology Virtual Congress.After a minimum follow-up of 35.5 months among patients treated with the combination of nivolumab and ipilimumab, 23% were alive at 3 years, …

 

Read the full article here


-- END RSP MOD -->